ClinicalTrials.gg
RecruitingNCT06010433Updated Nov 13, 2026

CERAMENT G Device Registry

An observational study in Chronic Osteomyelitis, Fracture Related Infection and Diabetic Foot Osteomyelitis, sponsored by BONESUPPORT AB. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by BONESUPPORT AB · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
31st of 58
100 · median 138
Started
2023
with 18 others
Observational
58 of 381
11 open now
Primary completion
2028-09
later than 77 of 83 live
Registered
292nd of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 31st largest by planned enrollment of the 58 observational ones that give a count, is one of 19 that started in 2023, is one of 58 observational ones, reaches primary completion later than 77 of the 83 other live ones, and was the 292nd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This is an Observational Device Registry Study of CERAMENT\|G in normal use in accordance with the IFU. It will run for a period of three years from enrolment of the first patient into the Study at each Site, before being subject to review. A Device Registry is a form of observational study that concerns the performance of a device in normal use. It is intended to collect data that is reflective of 'real world' device performance.

03

Conditions studied

  • Chronic Osteomyelitis
  • Fracture Related Infection
  • Diabetic Foot Osteomyelitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The racial, gender and ethnic characteristics of the individuals approached for participation in this Observational Registry Study shall reflect the demographics of patients that would ordinarily receive CERAMENT\|G for the treatment of their condition at the designated investigative centres. No individuals shall be excluded from participation in the Observational Registry Study based on race, nationality, ethnicity, gender, or sexuality

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and over (on the day of surgery)
  • receive CERAMENT\|G as a component of their treatment at a participating, contracted centre or healthcare provider, in accordance with the IFU for the implanted product
  • In receipt of patient information leaflet and have signed appropriately designed form.

Exclusion criteria

Exclusion Criteria:

  • Any exclusion criteria as per IFU for CERAMENT\|G
  • Any off-label use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • DeviceCERAMENT G

    * Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments. * Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing.

06

What researchers measure

Primary outcomes

  1. Primary Outcomes

    • Device safety - any unexpected device performance, complaints, adverse events, adverse device effects, SAEs throughout study period.

    Time frame: 12 months

Secondary outcomes

  1. Secondary Outcome

    Bone healing at final follow-up

    Time frame: 12 months

  2. Secondary Outcome

    Pain and functional assessment at whatever follow-up times are usual for the specific clinical site, for example 6 \& 12 months, if normally conducted

    Time frame: 6 and 12 months

  3. Secondary Outcome

    (Recurrence of) infection/revision surgery

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Sep 2028, 61 months after the start.

Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Aug 24, 2023
StartActual
Aug 17, 2023
Primary completionEst.
Sep 22, 2028
CompletionEst.
Sep 22, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and data sharing statement
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06010433
Lead sponsor
BONESUPPORT AB
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Aug 17, 2023
Primary completion
Sep 22, 2028 (estimated)
Completion
Sep 22, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Brian M Bartholdi
Contact
brian.bartholdi@bonesupport.com
16178923927

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion